Previous 10 | Next 10 |
Dosing is underway in a Phase 2 registrational trial in China evaluating I-Mab Biopharma's TJ202/MOR202, a fully human monoclonal antibody targeting a protein found on the surface of cancer cells called CD38, in patients with relapsed/refractory multiple myeloma (MM). The company in-lice...
Gainers: Inpixon (NASDAQ: INPX ) +68% . More news on: Inpixon, Mirum Pharmaceuticals, Inc., YayYo, Inc., Stocks on the move, Read more ...
Aduro BioTech (NASDAQ: ADRO ) -10% after Novartis bails on Aduro's ADU-S100 . More news on: Aduro BioTech, Inc., ADDvantage Technologies Group, Inc., FedEx Corporation, Stocks on the move, Read more ...
Allogene Therapeutics (NASDAQ: ALLO ) initiated with Market Perform rating and $37 (36% upside) price target at JMP Securities. More news on: Allogene Therapeutics, Inc., CorMedix, Inc., Fortress Biotech, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Aduro BioTech (NASDAQ: ADRO ) discloses that collaboration partner Novartis (NYSE: NVS ) has removed STING pathway activator ADU-S100 from its portfolio based on clinical data generated thus far. More news on: Aduro BioTech, Inc., Novartis AG, Healthcare stocks news, Read more ...
WEST JAVA, INDONESIA, Dec 3, 2019 - (ACN Newswire) - The 1st International Jatiluhur Jazz Festival (IJJF) 2019 took place on November 30 & December 1 at Indonesia's largest dam, the Jatiluhur Dam, in Purwarkarta, West Java. The IJJF was produced by Jasa Tirta II, the State-Owned Enterprise...
West Java, INDONESIA, Nov 26, 2019 - (ACN Newswire) - The 1st International Jatiluhur Jazz Festival is set to open at the Jatiluhur Dam in Purwakarta, West Java on Saturday and Sunday, Nov 30 and Dec 1, 2019. Presented by Jasa Tirta II, the State-Owned Enterprise (SOE) operating the dam, the l...
West Java, INDONESIA, Nov 23, 2019 - (ACN Newswire) - The 1st International Jatiluhur Jazz Festival is set to open at the Jatiluhur Dam in Purwakarta, West Java on Saturday and Sunday, Nov 30 and Dec 1, 2019. Presented by Perum Jasa Tirta II, the state-owned enterprise (SOE) operating the dam,...
BERKELEY, Calif., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of c...
Aduro Biotech (NASDAQ: ADRO ): Q3 GAAP EPS of -$0.26 misses by $0.03 . More news on: Aduro BioTech, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Aduro Biotech Inc. Company Name:
ADRO Stock Symbol:
NASDAQ Market:
The 15th Annual Global CSR & ESG Awards Honours 2023 Winners DA NANG, VIETNAM, Aug 30, 2023 - (ACN Newswire) - The 15th Annual Global CSR & ESG Summit & Awards ended on a high note before a full house in Da Nang, Vietnam, on August 28. Organized at the Novotel Danang Pre...
Combined Company Will H ave Over $275 Million in Operating Capital and Trade on Nasdaq under the Ticker Symbol “KDNY” VANCOUVER, British Columbia and SEATTLE, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Chinook Therap...
One-for-Five Reverse Stock Split to be Effective October 2, 2020 BERKELEY, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADURO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (ST...